FTL 008.7
Alternative Names: FTL-008.7Latest Information Update: 03 Nov 2024
Price :
$50 *
At a glance
- Originator Sound Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Sep 2024 Preclinical trials in Cancer in China (Parenteral), before September 2024 (Sound Biopharmaceuticals pipeline, September 2024)